Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

CDK Global has successfully renewed its DMS agreement with Sonic Automotive, securing a key partnership following two ...

In Hybrids amidst financial challenges. Read More CDK Global extends DMS contract with Sonic Automotive amid cyberattack ...

Charting, Price Performance, News & Related Contracts.

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Nereus Finance, a pioneering derivatives trading platform, is excited to announce the launch of its newest trading feature: ...

We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...

Charting, Price Performance, News & Related Contracts.

Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Tim Pearson, one of the most Mayor Eric Adams’ influential advisers, has submitted a letter of resignation less than a week after the mayor was indicted on ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...